CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	12 Months Ended
	Apr. 30, 2018	Apr. 30, 2017
Operating revenue:
Oncology solutions	$ 20,241	$ 15,411
Total operating revenue	20,241	15,411
Costs and operating expenses:
Cost of oncology solutions	10,553	9,703
Research and development	4,401	4,293
Sales and marketing	2,570	3,261
General and administrative	4,071	4,963
Total costs and operating expenses	21,595	22,220
Loss from operations	(1,354)	(6,809)
Other expense:
Other expense	(89)	(56)
Total other expense	(89)	(56)
Net loss before income tax expense	(1,443)	(6,865)
Provision for income tax	33	19
Net loss	$ (1,476)	$ (6,884)
Net loss per common share outstanding basic and diluted (in dollars per share)	$ (0.13)	$ (0.64)
Weighted average common shares outstanding basic and diluted (in shares)	10,991,105	10,684,395